2023
High-Dose Targeted Radiation with 131I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML
Litzow M, Chen G, Gyurkocza B, Nath R, Seropian S, Choe H, Abboud C, Koshy N, Tomlinson B, Abhyankar S, Foran J, Abedin S, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco J, Jamieson K, Magalhaes-Silverman M, Van Besien K, Schuster M, Law A, Mayer S, Lazarus H, Leung E, Chen M, Natwa M, Spross J, Li K, Nagl N, Haeuber E, Vusirikala M, Nahar A, Sandmaier B, Pagel J, Giralt S, Desai A, Wahl R, Pandit-Taskar N, Brodin P, Stiff P. High-Dose Targeted Radiation with 131I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML. Blood 2023, 142: 3529. DOI: 10.1182/blood-2023-189040.Peer-Reviewed Original ResearchDurable complete remissionConventional careLiver dosePrimary endpointBone marrowR AMLComplete remissionLiver ratioHigh doseLeukemic cellsRadiation doseAllogeneic hematopoietic cell transplantRadiation dose-response relationshipHematopoietic cell transplantMost older patientsPhase 3 studyTotal body irradiationFavorable biodistributionRadiation dose toleranceYears of ageDose toleranceDose-response relationshipDiseased bone marrowMedian doseRefractory AML
2019
Effect of drugs containing glucose on FDG-PET image quality
Okamoto S, Toyonaga T, Matsuzawa K, Aizawa M, Mouri T, Suzuki Y, Miyamoto N, Inubushi M. Effect of drugs containing glucose on FDG-PET image quality. Annals Of Nuclear Medicine 2019, 33: 828-834. PMID: 31407148, DOI: 10.1007/s12149-019-01394-1.Peer-Reviewed Original ResearchConceptsFDG-PETStandard uptake valueGrams of glucoseGroup CFDG-PET imagesPrescription drugsBrain/liver ratioFluorodeoxyglucose positron emission tomographySignificant differencesBrain/blood ratioQuantitative variablesBlood glucose levelsVisual scoresAmount of glucoseResultsIn group CPositron emission tomographyEffects of drugsBlood glucoseFDG injectionMethodsIn totalBlood ratioGroup BLiver ratioGlucose levelsGroup A
2014
Biodistribution and Radiation Dosimetry of LMI1195: First-in-Human Study of a Novel 18F-Labeled Tracer for Imaging Myocardial Innervation
Sinusas AJ, Lazewatsky J, Brunetti J, Heller G, Srivastava A, Liu YH, Sparks R, Puretskiy A, Lin SF, Crane P, Carson RE, Lee LV. Biodistribution and Radiation Dosimetry of LMI1195: First-in-Human Study of a Novel 18F-Labeled Tracer for Imaging Myocardial Innervation. Journal Of Nuclear Medicine 2014, 55: 1445-1451. PMID: 24994931, DOI: 10.2967/jnumed.114.140137.Peer-Reviewed Original ResearchConceptsAdministered activityBlood-pool standardized uptake valuesPhase 1 clinical trialCardiac nerve terminalsCardiac imagingMSv/MBqMean effective doseStandardized uptake valueRadiation doseOLINDA/EXMPatient radiation doseRadiation dose estimatesAdverse eventsBlood pressureWhole-body imagesClinical trialsBlood radioactivityMyocardial innervationNerve terminalsUrinary bladderHealthy subjectsLiver ratioHeart rateLung activityMyocardial uptake
1995
Technetium-99m-nitroimidazole (BMS181321): a positive imaging agent for detecting myocardial ischemia.
Shi CQ, Sinusas AJ, Dione DP, Singer MJ, Young LH, Heller EN, Rinker BD, Wackers FJ, Zaret BL. Technetium-99m-nitroimidazole (BMS181321): a positive imaging agent for detecting myocardial ischemia. Journal Of Nuclear Medicine 1995, 36: 1078-86. PMID: 7769431.Peer-Reviewed Original ResearchConceptsIschemic regionMyocardial ischemiaBlood flowEx vivo SPECTRegional myocardial blood flowPartial coronary occlusionMicrosphere blood flowMyocardial blood flowOpen-chest canine modelVivo SPECT imagesSPECT imagesVivo planarCentral ischemic regionCoronary occlusionDemand ischemiaBMS181321Technetium-99mIntravenous injectionLiver ratioMyocardial imagingCanine modelPositive imagingHepatic clearanceLiver activityArterial sampling
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply